

## Review

# 50 Years of Preclinical Anticancer Drug Screening: Empirical to Target-Driven Approaches

Marie Suggitt and Michael C. Bibby

Tom Connors Cancer Research Centre, University of Bradford, Bradford, United Kingdom

### ABSTRACT

The number of anticancer agents that fail in the clinic far outweighs those considered effective, suggesting that the selection procedure for progression of molecules into the clinic requires improvement. The value of any preclinical model will ultimately depend on its ability to accurately predict clinical response. This review focuses on the major contributions of preclinical screening models to anticancer drug development over the past 50 years. Over time, a general transition has been observed from the empirical drug screening of cytotoxic agents against uncharacterized tumor models to the target-orientated drug screening of agents with defined mechanisms of action. New approaches to anticancer drug development involve the molecular characterization of models along with an appreciation of the pharmacodynamic and pharmacokinetic properties of compounds [e.g., the US National Cancer Institute (NCI) *in vitro* 60-cell line panel, hollow fiber assay, and s.c. xenograft]. Contributions of other potentially more clinically relevant *in vivo* tumor models including orthotopic, metastatic, and genetically engineered mouse models are also reviewed. Although this review concentrates on the preclinical screening efforts of the NCI, European efforts are not overlooked. Europe has played a key role in the development of new anticancer agents. The two largest academic drug development groups, the European Organisation for Research and Treatment of Cancer and Cancer Research UK, have been collaborating with the NCI in the acquisition and screening of compounds since the 1970s. As with the drug development process internationally, rational pharmacodynamic approaches have more recently been adopted by these two groups.

Received 8/27/04; revised 10/28/04; accepted 11/10/04.

**Grant support:** Biotechnology and Biological Sciences Research Council and AstraZeneca Studentship Case Award funding (M. Suggitt), and Cancer Research UK grant C6698/A2580 (M. Bibby).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

**Requests for reprints:** Marie Suggitt, Tom Connors Cancer Research Centre, University of Bradford, Bradford, BD7 1DP, United Kingdom. Phone: 44-1274-234271; Fax: 44-1274-233234; E-mail: m.suggitt1@bradford.ac.uk.

©2005 American Association for Cancer Research.

### TUMOR MODELS (1955-1985)

In 1955, following reports that the correlation between compound efficacy against transplanted tumors and clinical activity was substantially better than the previously used mammalian cell and bacterial cultures (1), the National Cancer Institute (NCI) began a large-scale anticancer drug screening program testing agents against a panel of three mouse tumor models: sarcoma 180, L1210 leukemia, and carcinoma 755 (2–6). In 1965, screening was limited to the use of only the L1210 and Walker 256 carcinosarcoma murine models, and by 1968, synthetic agents were screened in L1210 alone, whereas natural plant products were screened in L1210 and P388 leukemias. In 1972, B16 melanoma and the Lewis lung carcinoma mouse models were introduced (6–8). The reliance on the L1210 model in the first 25 years of anticancer drug screening raised concerns that screening against a rapidly growing animal leukemia may have resulted in preferential selection of drugs that were only active against rapidly growing tumors (9). During this time, clinical response of human leukemias and lymphomas improved (10, 11), whereas treatment response was less promising for most human solid tumors. As a consequence, in 1976 the Division of Cancer Treatment at the NCI introduced a new tumor panel incorporating transplantable solid “human” tumor models that were representative of the major histologic types of cancer prevalent in the United States at the time. This development followed the revolutionary discovery of the nude athymic (*nu/nu*) mouse (12) and the successful growth of human tumor xenografts (13). The panel consisted of matched animal and human tumors of the breast (CD8F<sub>1</sub>/MX-1), colon (colon 38/CX-1), and lung (Lewis/LX-1), along with the L1210 leukemia and B16 melanoma syngeneic models (6, 9). Syngeneic models involved inoculation i.p., s.c., or i.v., whereas human tumor xenografts were grown under the subrenal capsule (14). The subrenal capsule assay uses small tumor fragments growing under the renal capsule of athymic mice and normal immunocompetent mice (14). Although the subrenal capsule assay was labor-intensive, it provided a rapid means of evaluating new agents against human tumor xenografts at a time when longer-term s.c. assays were not feasible. The subrenal capsule assay has shown good predictive value of clinical response with an overall evaluable assay of 90% (15).

Prior to testing against this new “mouse-human” tumor panel, compounds were subjected to a relatively cost-effective *in vivo* “prescreen” using the P388 model. This model was sensitive to most classes of clinically effective drugs, yet was sufficiently discriminating to avoid overloading the panel (16).

It was revealed that this mouse-human tumor panel (1976–1982) identified antitumor agents (e.g., taxol) that would have been missed by the L1210 model alone (9). Approximately 30% of compounds found to be active in at least one human tumor xenograft were missed by syngeneic models. Therefore, the

mouse-human tumor panel successfully achieved the goal of providing new agents for clinical trial, although the correlation between preclinical screening and clinical efficacy was found to be extremely low (17). This was thought to reflect either the poor predictivity of selection strategies or the low number of active compounds that actually existed.

Subsequently, in 1982 the NCI employed a new strategy involving a sequential process of “progressive selection” whereby a compound was presented with a progressively greater biological and pharmacologic challenge at each stage. Compounds were first subjected to the P388 prescreen model, and then a standard panel including tumor models known to produce a relatively high-yield of active compounds (MX-1, B16, and L1210). A new model, the M5076 sarcoma as well as advanced and multidrug-resistant tumor models, were incorporated in this standard panel (9). Agents found to be active in the standard tumor panel were subjected to secondary screening. The selection of secondary tumor models was “drug-orientated.” Agents were subjected to specific tumor models based on the known properties of each individual compound and previous experience in the standard tumor panel.

At this time, several retrospective preclinical-clinical correlation studies were reviewed (18), but no apparent positive correlation between preclinical and clinical efficacy based on tumor type was found. It was suggested that the lack of histologically based correlations may be a consequence of experimental design which limited tumors to one mouse and one human correlation for each of the three major types. It was also suggested that a “model system” composed of several tumors of the same type might, on the basis of percentage responders, predict for a reasonable clinical response rate against similar type tumors (18).

### **HUMAN TUMOR STEM CELL ASSAY/ CLONOGENIC ASSAY**

The development of the human tumor stem cell (HTSC) assay (19–21) offered an approach to determine whether using a model system composed of several tumors of the same type may be better at predicting a reasonable clinical response than previous *in vivo* tumor models (9). The HTSC assay was disease-orientated in concept and involved the growth on soft agar of colonies derived from freshly explanted human tissue. Compounds were tested against tumor colonies and activity defined by the growth inhibition of colonies. Salmon and colleagues (19) compared *in vitro* results to the clinical responses of myeloma and ovarian cancer patients and the study showed clear correlations and unique patterns of sensitivity and resistance. This study showed sufficient promise to warrant larger-scale testing to determine the efficacy of the HTSC assay for selecting clinically active agents and individualizing cancer treatment.

The applicability of the HTSC assay for drug screening purposes in terms of feasibility, validity, and potential to identify new antitumor agents was investigated (22). The testing of established standard chemotherapeutic agents in this pilot study revealed that most agents were found to be active with the exception of those requiring systemic activation. Clinically ineffective agents were confirmed to be true negatives with 97%

accuracy. Other groups also showed the potential use of the assay in predicting clinical activity (23–29). Typically, an assay was shown to predict drug resistance with 90% accuracy and clinical drug sensitivity with between 40% and 70% accuracy. Additionally, of 79 compounds found previously to be inactive using the P388 prescreen, 14 were active in the HTSC assay. Reproducibility of survival values within assays and between laboratories was also revealed.

However, several limitations prevented the use of this assay for large-scale screening (29–31), the main criticism being that many tumor types have a low plating efficiency. Subsequently, only breast, colorectal, kidney, lung, melanomas, and ovarian tumors produce a sufficient yield of evaluable assays. Hence, the number of patients for whom treatment may be chosen by clonogenic assays was frequently <50%, although recently the growth rates of primary tumor tissues in the HTSC assay has significantly improved (70–80%; ref. 29). Additional problems encountered include labor intensity, automation, and difficulty in attaining a single cell suspension from human solid tumors. Clonogenic assays also include sources of substantial error, and quantification of data, cell survival curves, and colony size are often criticized (29–31).

To date, there are no phase III clinical studies of individualized therapy demonstrating a significant increase in survival compared with empirically determined standard treatment, therefore the clonogenic assay has not found a practical established role in the individualization of patient therapy (29). Clonogenic assays are still widely used as a secondary screen by independent researchers (29, 31, 32). At the Institute for Experimental Oncology in Freiburg, an *in vitro/in vivo* testing procedure is employed using target-defined tumor models. Patients' tumors are tested directly in the *in vitro* clonogenic assay, or after being established as a permanent xenograft model. Agents are tested using both an empirical and target-orientated screening strategy. In addition to the routine end point of the clonogenic assay (inhibition of colony growth), pharmacodynamic assays are employed to determine compound activity (29).

### **HUMAN TUMOR *IN VITRO* CELL LINE SCREEN, 1985 to PRESENT DAY**

In 1985 the phase-down of the *in vivo* P388 prescreen, HTSC assay and the human/murine tumor panels began. The feasibility of employing human tumor cell lines for large-scale drug screening was investigated (33). At the time, it was appreciated that this new program could have the potential to rapidly evaluate a large number of anticancer agents, yet it was argued that “appropriate” transplantable mouse tumors should still have their place in the drug development program and involve a broader preclinical evaluation (i.e., pharmacokinetics, toxicology, metabolism, drug bioavailability, and therapeutic index; refs. 34, 35). With regard to therapeutic index, dose-limiting toxicity in human is sometimes difficult to predict from mouse studies (e.g., bone marrow toxicity and neurotoxicity).

This new *in vitro* human tumor cell line screen initiated in April 1990, shifted the NCI screening strategy from being “compound-orientated” to “disease-orientated.” The initial cell line panel incorporated a total of 60 different human tumor cell

lines of diverse histologies derived from seven types of cancer (brain, colon, leukemia, lung, melanoma, ovarian, and renal), including drug-resistant cell lines. Thus, like the HTSC assay, the *in vitro* 60-cell line screen offered an approach to use several tumors of the same type. In December 1992, 10 of the original cell lines were replaced by a selection of breast and prostate cancer cell lines (36).

To date ~85,000 compounds have been screened against this *in vitro* cell line panel in a short-term assay (37), whereby the nonclonogenic protein stain sulforhodamine B assay (38) is used to determine cell viability. Each compound is tested over a 5-log concentration range against each of the 60 cell lines in a 2-day assay and generates 60 dose-response curves. These data generate a characteristic profile or “fingerprint” of cellular response, i.e. the “mean graph” (39). “COMPARE” is a computerized, pattern recognition algorithm used in evaluating and exploiting the fingerprint data in order to determine the degree of similarity between mean graph profiles generated by similar or different compounds (39).

Initial studies revealed that compounds matched by their mean-graph patterns often had related chemical structures. Closer examination of this phenomenon led to the realization that compounds of either related or unrelated structures, and matched by their mean-graph patterns, frequently shared the same or related biochemical mechanisms of action.

In contrast to fingerprints with pattern similarity to standard agents in the database, compounds have been detected which produce striking differential cytotoxicity fingerprints. These “COMPARE-negative” agents indicate that they have a unique mechanism of action.

Since the early 1990s, data on the expression of molecular characteristics within the 60-cell human tumor panel has been accumulated. The implication of this being that the sensitivity of a cell line, along with knowledge of its molecular characteristics may indicate that a compound’s cytotoxicity is mediated by its interaction with a known molecular target. Alternatively, differential expression in the form of a mean graph of particular molecular markers (e.g., MDR1/p-glycoprotein) may indicate why particular cell lines may be resistant to a test compound (40). An extensive collection of molecular target data exists including kinases, phosphatases, genes associated with cell cycle control, apoptosis, DNA repair, signal transduction, oncogenes, and drug metabolizing reductase enzymes (<http://dtp.nci.nih.gov>) (ref. 37).

In 1999 an *in vitro* prescreen was introduced whereby compounds were screened in a three-cell line panel using three highly sensitive cell lines, MCF-7 (breast carcinoma), NCI-H460 (lung carcinoma), and SF-268 (glioma). The rationale for this prescreen was the observation that 85% of compounds screened in the past had shown no evidence of antiproliferative activity, and a three-line prescreen was shown to efficiently remove many of the inactive compounds from unnecessary and costly full-scale evaluation in the 60-line panel.

Three end points are used to determine compound activity and whether a compound will be considered for further evaluation. These are GI<sub>50</sub> (concentration required to inhibit 50% of cells), total growth inhibition, and LC<sub>50</sub> (concentration required to kill 50% of cells; ref. 37). Compounds possessing disease specificity or that are COMPARE-negative are also referred for secondary *in vivo* screening, initially using the

hollow fiber assay (HFA; ref. 41). Compounds considered active in the HFA are prioritized for *in vivo* xenograft testing.

The present human tumor cell line *in vitro* screen is technically simple, relatively fast, cheap, reproducible, and provides valuable indicative data of mechanistic activity and target interaction. Yet it is not without its limitations. *In vitro* methods are susceptible to false-positive and false-negative results. It is also clear that factors other than the inherent chemosensitivity of tumor cells significantly influence the outcome of chemotherapy *in vivo* (e.g., pharmacokinetics, tumor microregions/pH, and pO<sub>2</sub>; refs. 34, 42). Such factors are not represented by the *in vitro* 60-cell line screening assay, yet it is appreciated that this assay was designed only to select compounds for a secondary, more comprehensive, *in vivo* testing. The original intention of the NCI/DTP was to produce a high-throughput *in vitro* screen that would be sufficiently discriminatory to ensure that only a relatively small number of compounds would be selected for further evaluation in human tumor xenograft models. This has not been the case and subsequently the *in vivo* HFA was implemented in 1995 in attempt to prioritize compounds for secondary xenograft screening and help reduce the large number compounds that were forming a bottleneck for entry into secondary xenograft testing.

## THE HOLLOW FIBER ASSAY

Based on previous microencapsulation and hollow fiber culture systems (43–45), Hollingshead and colleagues (41) developed the HFA designed to identify *in vivo* activity of potential anticancer compounds. The HFA assesses the pharmacologic capacity of compounds to reach two physiologic compartments within the nude mouse and shows a practical means of quantifying viable tumor cell mass.

In 1995, due to the feasibility of growing over 50 human tumor cell lines within biocompatible hollow fibers and the relatively rapid and cost-effective demonstration of *in vivo* activity compared with xenograft models, the NCI employed the HFA as a routine preliminary *in vivo* screening assay. Although xenograft models have in the past proved invaluable in developing current chemotherapeutic agents, they are accompanied by various limitations including high costs associated with large-scale screening, time, and number of mice required. Additionally, the empirical dosing and development of pharmacokinetic assays for each compound evaluated in xenograft models would greatly reduce the rate at which compounds could progress to the clinic (46).

The current NCI HFA protocol involves the short-term *in vitro* culture (24–48 hours) of a panel of 12 cell lines inside hollow fibers, followed by *in vivo* implantation at both s.c. and i.p. sites of the nude mouse. The assay has the potential to simultaneously evaluate compound efficacy against a maximum of six cell lines (three cell lines/fibers per site). Mice are treated with test compound at two doses for up to 4 days, fibers excised and analyzed for cell viability using a modified 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. Compounds are identified as active using a detailed scoring system and optimal or near-optimal treatment regimens are indicated for subsequent testing using xenograft models (41, 46).

In contrast to the use of the HFA as a rapid *in vivo* screening model, independent research groups have more recently used the HFA to investigate the pharmacodynamics of anticancer agents *in vivo*. Authors have taken advantage of the practical feasibility of pure cell population retrieval and have used a target-orientated approach for the evaluation of compound activity. Pharmacodynamic end points investigated include protein/gene/mRNA expression, tubulin/DNA damage, and cell cycle disruption (47–51). Other groups have also used the HFA to investigate specific areas of tumor biology (52, 53). Primary human tumor cells have also been cultivated within fibers *in vivo* (54). Such studies have been undertaken in an attempt to use this relatively rapid *in vivo* test system to predict patient response in the clinic.

Supportive evidence for the use of the HFA as an *in vivo* prescreen is derived from the good predictivity of *in vivo* xenograft activity (46, 47, 55, 56). Initial proof-of-concept, assay development, and validation studies, whereby compounds were tested in both *in vivo* xenograft and hollow fibers, have indicated that a xenograft-positive compound was unlikely to be missed by testing in the HFA (55).

Johnson and colleagues (56) showed that the likelihood of finding xenograft activity in at least 1/3 of *in vivo* models rose with increasing i.p. activity. This correlation was not evident with s.c. fibers. It has been suggested that there may be insufficient time for angiogenesis to occur at the s.c. site, thereby limiting drug delivery (57). Arguing against this hypothesis, Hollingshead and colleagues (58) showed the delivery of luciferin to the s.c. site within 6 minutes following i.p. administration 3 hours after *in vivo* implantation. In this novel study, hollow fibers were seeded with tumor cells transfected with the luciferase gene and implanted in nude mice. Bioluminescence permitted the monitoring of tumor growth within fibers *in vivo*. Consistent with this study, a more recent evaluation of the predictive value of the HFA indicates that the greater the response in the HFA (including s.c. site) the greater the likelihood that a compound will display activity in the xenograft model (46).

A strong correlation between potency in the 60-cell line screen and the HFA has also been reported (56), providing strength for the argument that the HFA is unlikely to miss active agents at this preliminary filtering *in vivo* stage.

Initially (1995–1999), compounds defined as active in the HFA were tested in a series of xenograft models in a range of histologies encompassing the sensitive cell types determined in hollow fibers. However, in 1999, the development of agents based purely on empirical antitumor activity in human tumor xenografts without definition of an agent's biological target was abandoned (59). New evolving strategies seemed to be in response to the advent of a new era of small molecule anticancer therapeutics that were replacing classic cytotoxic agents. Because this time positive hollow fiber results were used to prioritize compounds for further pharmacologic and mechanistic studies (46). Hollow fiber studies are accompanied by an effort to define the pharmacokinetics (peak concentration and area under the concentration  $\times$  time curve) associated with drug activity.

The current NCI HFA does not specifically define any precise mechanisms of drug action that may have previously been indicated by the recent molecular characterization of the

*in vitro* human tumor 60-cell line screen from which compounds have progressed. It would seem logical to follow up any indication of a compound's mechanism of action using the relatively rapid and cost-effective hollow fiber model.

It is proposed that the continued use of the HFA will exploit its ability to define specific pharmacodynamic end points at this early stage in a drug's evaluation (46) as has been shown previously (47–51). This may allow further refinement in lead selection through immunohistochemical, genomic, proteomic, and enzyme assays of cells extruded from fibers excised from drug-treated mice (46).

## HUMAN TUMOR XENOGRAFTS IN SECONDARY SCREENING

Before the implementation of the HFA (1990–1995), each agent was evaluated in the murine P388 model and three s.c. human tumor xenograft models defined as the most sensitive *in vitro* (60).

Between 1995 and 1999, compounds defined as active in the HFA were evaluated in three s.c. xenograft models using the most sensitive tumors identified by the HFA (60). Approximately 40% of compounds showed sufficient activity in the HFA and were selected for further *in vivo* testing. Therefore, a significant number of compounds were filtered out at this preliminary *in vivo* stage which would otherwise have used a significant amount of more costly *in vivo* resources. At the same time, specific assays were carried out to determine the pharmacologic/biological properties of a compound (60).

Xenograft tumors are generally established by the s.c. inoculation of tumor cells into nude mice ( $1.0 \times 10^7$  cells per mouse). Growth of solid tumors is monitored using *in situ* caliper measurements and models may be advanced stage or early stage (6, 61). Generally, activity is defined by tumor growth delay, optimal % T/C (T/C - median treated tumor mass/median control tumor mass) or net log cell kill. Drug-related deaths and body weight loss are used as parameters of toxicity.

Many compounds have shown promising activity in s.c. xenograft models, progressed to the clinic and revealed disappointing results. As a result, there has been considerable debate regarding the value of the xenograft model.

Despite enormous efforts to discover new chemotherapeutic drugs for treating the most common cancers, the conventional murine and xenograft test systems have identified only a limited number of useful agents that are clinically active at well-tolerated doses. Despite this, chemotherapeutic agents used routinely in the clinic today have played a significant role in reducing the mortality/morbidity, increasing the survival, and improving the quality of life of cancer patients. Chemotherapy may be given before, after, or in combination with surgery or radiotherapy. Indeed some agents have had a great beneficial impact on the survival of cancer patients, such as tamoxifen (UK-based pharmaceutical company ICI, now AstraZeneca, Macclesfield, United Kingdom) in the treatment of breast cancer. Moreover, testicular cancer has proven to be curable using chemotherapy (bleomycin, etoposide, and cisplatin).

Several groups have detailed studies supporting the value of the s.c. xenograft model for predicting clinical activity. Fiebig and colleagues (29, 62) established a large panel of xenografts

derived from patient biopsies, and activity in xenografts was compared with clinical response. A correct prediction of clinical outcome was observed for both tumor resistance (97%) and tumor sensitivity (90%). These results also revealed that the xenograft model was more predictive of clinical activity than the clonogenic assay. Thus, it seems likely that well-characterized *in vivo* models which are more biologically representative of patient tumors may be more predictive of clinical response than uncharacterized *in vivo* models (29).

These results corroborate early studies comparing the activity of standard agents against xenograft models and clinical response (63). During the 1980s, several groups established disease-specific panels of xenografts from patient biopsies and correlated xenograft activity with patient response (61).

The NCI reported results of a retrospective study whereby 39 agents with both xenograft and phase II clinical trial results were compared (56). *In vivo* xenograft activity of a particular histology did not closely correlate with activity in the same human cancer histology. However, for compounds with activity in at least 1/3 of xenografts, there was a correlation with ultimate activity in at least some clinical trials.

Many of the agents tested in this study are standard chemotherapeutic agents used today (e.g., paclitaxel and doxorubicin; ref. 56).

With respect to the development of cytotoxic agents, the s.c. xenograft model does seem to have value as a predictive *in vivo* preclinical model (29, 56, 61, 63). However, the view that xenograft tumors (uncharacterized at the molecular level) are poorly predictive of the same histologic type of tumor in patients has influenced the initiation of the current strategy employed by the NCI's drug discovery and development program (59). Specifically, the *in vitro* 60-cell human tumor line screen is used to indicate possible mechanisms of drug action. Further development occurs only after an effort is made to have a molecular end point of the compound's action, and defining a subset of tumors likely to respond to the agent that possesses the intended target. Pharmacologic scheduling and toxicology studies are done prior to target-directed phase I studies (59).

Many agents undergoing anticancer drug development at present are not cytotoxic agents but are small molecules rationally designed to inhibit fundamental processes known to be involved in the initiation and/or progression of human malignancy. Common target molecules include Bcr/Abl kinase in chronic myelogenous leukemia, c-kit in gastrointestinal stromal tumors, and erbB2/HER-2 oncogenic receptor tyrosine kinase in breast cancer. A comprehensive review of current molecular drug targets is provided elsewhere (64). The discovery of such molecular targets has been accelerated by recent technical innovations such as high throughput genomic/proteomic technology.

It is anticipated that the s.c. xenograft model will still be of value in this modern era of target-driven anticancer drug discovery if used appropriately. Specifically, it is becoming more and more appreciated that xenograft models should be characterized to ensure that the molecular drug target is expressed (46, 59, 61, 65, 66) and that xenograft studies should integrate both pharmacokinetic and pharmacodynamic investigation (34, 46, 59, 61, 67, 68).

The comparative analysis done by the NCI on clinical and xenograft activity found that only non-small cell lung xenografts were predictive of response in this histology in patients (56). In this study, xenografts were derived from cell lines that had been cultured over a long period, and it is likely that such xenografts no longer retained the original molecular characteristics of the patient tumor. In contrast Fichtner and colleagues (69) recently established human tumor xenografts directly from patient tumors that were characterized for specific molecular markers of the original patient tumor. The response to chemotherapy of these patients coincided very closely with the response of the individual xenografts. These data support previous work whereby fresh tumor explants were grown as xenografts and activity was found to show good correlation with clinical outcome (29). Together, these studies show that xenograft models which closely mimic the clinical situation are valuable models in predicting clinical outcome, and it is also emphasized that such molecularly characterized xenograft models may serve as valuable tools in the target-orientated drug development of specific rationally designed small molecules (69).

In line with this approach, a recent initiative by the NCI/Cancer Treatment Evaluation Program and the Children's Oncology Group aims to characterize available models of childhood tumors through proteomic and genomic profiling (Pediatric Oncology Preclinical Protein Tissue Array Project). These data will be of value in selecting xenografts for preclinical testing of molecular targeted therapies (68).

Retrospective analysis of pharmacokinetic and pharmacodynamic parameters in preclinical and clinical studies can often logically explain the failure of compounds in the clinic (68, 70). For instance, plasma concentrations required for antitumor activity in mice may be in excess of that achievable in man, and may even cause toxicity at lower doses in man. It has been suggested that the failure of conventional cytotoxic drugs in the clinic may be due to such inappropriate drug dosing (67).

Human tumor xenografts have been shown to be remarkably predictive of clinical cytotoxic therapy for a given type of cancer provided that clinically relevant pharmacokinetic parameters (i.e., dosing) are employed (67, 68, 70). For instance, Nomura, Inaba and colleagues at the Cancer Chemotherapy Centre, Japanese Foundation for Cancer Research, Tokyo, Japan, and Houghton and colleagues at St. Jude's Children's Hospital, Memphis, USA, gave clinically relevant or rational doses in preclinical s.c. xenograft models and found that the pattern of response in mice was similar to the activity in the respective human cancer with the same drugs (67). Such studies emphasize the need for the determination of exposure levels required to cause an antitumor effect in xenografts so that clinical trials may be coordinated accordingly and unnecessary toxicity avoided.

## ORTHOTOPIC AND METASTASIS TUMOR MODELS

As described previously, compounds are usually screened against a panel of poorly characterized human tumor xenografts implanted s.c. in nude mice. S.c. tumor models do not represent the primary site of common human cancers or sites of metastasis (66). It has been suggested that the disparity between preclinical and clinical activity is related to the treatment of advanced

metastatic disease in the clinic, whereas conventional s.c. xenograft models do not represent advanced metastatic disease nor is the orthotopic site represented (67). Orthotopic transplantation models attempt to mimic the morphology and growth characteristics of clinical disease (71–75) and are thought to represent a more clinically relevant tumor model with respect to tumor site and metastasis (76). One of the most obvious advantages of orthotopic systems is that attempts to target processes involved in local invasion (e.g., angiogenesis) can be carried out in a more clinically relevant site (66). Several other models are also used to assess the antiangiogenic properties of novel agents (e.g., corneal micropocket assay; ref. 77). Since the early studies showing orthotopic transplantation of colon tumors and metastasis to the liver (78), tumor material has been grown orthotopically in mice at most common sites of human cancer. Whether preclinical models representative of clinical disease (e.g., orthotopic/metastatic models) should be employed as a replacement for traditional s.c. nonmetastatic xenografts (67, 74) is an interesting question.

There are several key preclinical studies describing the disparity of activity in s.c. and orthotopic models in relation to the success of compounds in the clinic (66, 79–81). Although these studies provide convincing argument that orthotopic models may be the more appropriate model for the prediction of clinical response, this remains to be seen. Orthotopic models have also been observed to falsely predict clinical activity (e.g., batimastat; ref. 82). It has been suggested that further studies using current chemotherapeutic agents against s.c. and orthotopic models of common types of cancer may help confirm this (66).

Despite the obvious clinical relevance of orthotopic models, their application is hindered by several disadvantages. In contrast to conventional s.c. tumor xenografts, limitations include technical skill, time, and cost. Therapeutic efficacy is also more difficult to assess in contrast to the relative ease of s.c. tumor measurements (66).

The characterization of metastasis models may be evaluated more easily with the use of noninvasive microimaging research tools (66, 83, 84). Recent technological advances have had a major impact on research using orthotopic models for studying the process of cancer metastasis. Magnetic resonance imaging and positron emission tomography are being used to visualize tumor and metastasis progression. Reporter genes with specific fluorescence properties have been developed including the stable green fluorescent protein (83), galactosidase lacZ gene (85), and the luciferase gene (86). Although such technology is not widely used, it has permitted the visualization of tumor growth using ethically more acceptable noninvasive techniques and has reduced the numbers of animals required for orthotopic and metastasis studies.

## AUTOCHTHONOUS MODELS

Autochthonous tumors include spontaneously occurring tumors and induced tumor growth (e.g. by chemical, viral, or physical carcinogens). It is thought that autochthonous tumors may mimic human tumors more closely than transplanted tumors (i.e., s.c./orthotopic). Advantageous properties include orthotopic growth, tumor histology devoid of changes introduced by

transplantation, and a route of metastasis through lymph and blood vessels that surrounded early tumor growth (87).

Despite such properties, the use of autochthonous tumor models has not been widespread due to several limitations. A large variability in take rate and growth exists, the large number of animals needed, time frames of several months to years exist for a single experiment due to long tumor latencies as opposed to weeks in transplanted xenograft models, and lack of spontaneous metastasis (84, 87). Autochthonous models are used occasionally as tools for advanced or phase II screening (87), but more recently in this “postgenome era” autochthonous models have largely been replaced by genetically engineered mouse (GEM) models.

## GENETICALLY ENGINEERED CANCER MODELS

Over the past 20 years, GEM models have made a significant contribution to the field of cancer research. GEM models have increased our understanding of the molecular pathways responsible for the initiation and progression of human cancer, and have highlighted the importance of specific oncogenes and tumor suppressor genes (TSG) in particular types of cancer.

GEM models possess well-validated molecular/genetic characteristics (e.g., gene mutations) which ultimately facilitate the rational design of small molecule therapeutics (88).

The main aim of GEM models is to recapitulate genetic/molecular changes in human cancer and use these to test novel anticancer therapeutics in an attempt to accurately predict clinical response.

The first strains of genetically engineered mice predisposed to cancer were transgenic mouse models whereby cellular/viral oncogenes were introduced to the mouse germ line. One of the first transgenic cancer models involved the constitutive expression of the *c-myc* oncogene under the control of the mouse mammary tumor virus promoter leading to the development of mammary tumors (89). Many transgenic experiments have followed and clearly shown that the manipulation of the mouse germ line could predispose the mice to cancer (90).

Upon the discovery that the progression to a malignant phenotype often involves the loss of TSG function (91), transgenic mouse models were developed which involved introducing a mutant TSG to the mouse germ line. TSG function can be impaired by either targeted gene knockout (92) or the transgenic expression of a dominant-negative form of the TSG (93). One of the first TSG mutants was the Rb “knockout” mouse (94). Mice heterozygous for a null Rb allele developed tumors (pituitary adenocarcinomas, medullary thyroid carcinoma, and/or pheochromocytomas). Since the Rb knockout, many mutant TSG or knockout cancer-prone mouse models have been developed including p53 (94–96), Apc (97), Nf-1 (98), and many more reviewed elsewhere (88, 99–101).

Alternatively, mouse models have been developed by inducing germ line mutagenesis. For instance the *Min* (multiple intestinal neoplasia) mouse was created by germ line mutagenesis using *N*-ethyl-*N*-nitrosourea, which causes a point mutation in the Apc TSG (102). The most common human cancer, basal cell carcinoma, has also been modeled by the exposure of *Ptch*

heterozygous mice to UV light (103). Etiologic factors such as diet are also being modified and have been shown to affect tumor development in GEM models (104, 105).

It is well known that cancer is a multistep process involving several sequential mutations (106), and in the light of this finding, different mouse strains of known genetic background have been interbred in an attempt to identify any cooperativity between oncogenes and TSGs in the progression towards the malignant phenotype (88). Sinn and colleagues (107) clearly showed that when two transgenic mouse strains individually expressing *c-myc* and *v-ras* were crossed, resultant progeny developed mammary gland carcinoma at a much greater rate (synergistically) than transgenic mice expressing only one oncogene. This study clearly indicated that *c-myc* cooperated with *v-ras* in the progression towards malignancy in mammary gland tumorigenesis *in vivo*.

There are several existing mouse models of multistep tumorigenesis. The RIP-Tag mouse expresses the SV40 antigen under the control of the insulin promoter leading to the development of pancreatic islet cell carcinoma (108). The analysis of the genetic/histologic changes occurring during tumor progression in the RIP-Tag model has identified specific molecular markers associated with apoptosis, angiogenesis, and cell adhesion (e.g., Bcl-X<sub>L</sub> and E-cadherin) at specific stages (88, 109–113).

Transgenic and knockout approaches can also be used to evaluate the role of specific components of the tumor microenvironment (e.g., matrix metalloproteinase 9) in tumor progression. The chemically induced skin carcinoma model (114) is another well-explored model that mimics more than one stage of tumor progression with defined genetic/molecular characteristics [*H-ras* activation, up-regulation of cyclin D1, loss of p53, and up-regulation of transforming growth factor- $\beta$ 1 (88)].

Transgenic and knockout mouse models involving manipulation of the mouse germ line are often limited by embryonic lethality. In an attempt to overcome this, several new approaches to create GEM strains have been introduced, including transient conditional gene targeting, latent oncogenes, inducible oncogene expression and the use of avian sarcoma leucosis viruses, and chromosome engineering (88, 115–118). These novel methods have been facilitated by recent technological advances [e.g., cytogenetic (spectral karyotyping), genomic comparative genomic hybridization, comparative genomic hybridization microarrays, and gene expression profiling; refs. (119, 120)].

Conditional transgenic/knockout models involve spatial control over the initiation of oncogene expression and TSG inactivation, respectively, and have been used to create models of several types of cancer (115). The Cre-Lox system is the most widely used for both transient conditional knockout (121) and oncogene expression (122). Another new approach in creating mouse models involves latent mutant alleles that become expressed following somatic recombination *in vivo* (123). Inducible oncogene expression involves the tissue-specific expression of oncogenes in response to stimulation by small molecules (e.g., doxycycline and tamoxifen; ref. 115). Avian sarcoma leucosis viruses are also employed to deliver oncogenes and dominant-negative forms of TSGs to cells *in vivo* that express the avian sarcoma leucosis virus retroviral receptor (124).

Unlike xenograft models, GEM models possess well-validated drug targets and may potentially offer a more appropriate preclinical model in which to test modern small molecule therapeutics. Additionally, GEM tumors develop autochthonously/*in situ* and therefore may be more biologically representative of a particular tumor type in humans than transplanted xenografts. Despite such promise, GEM models are not without limitation. Compared to the traditional xenograft model, GEM models are expensive and time-consuming. Their use is often restricted by intellectual property rights and patents (125). In addition to embryonic lethality, mice often do not develop the expected tumor type as they may die prematurely from a different tumor type caused by the constitutive expression of oncogene/TSG. Species-specific differences also exist in the role of different genes in different cell types, which can lead to different mutant phenotypes in both man and mouse (126). For instance, transgenic Rb mice heterozygous for a null Rb allele developed pituitary adenocarcinomas, medullary thyroid carcinoma, and/or pheochromocytomas, whereas this same mutation in man causes retinoblastoma (127).

It is not usually a primary tumor which kills a patient, but metastatic disease, and unfortunately this advanced stage is not represented by most GEM models (101, 116). In comparison to traditional xenograft models, very few studies have shown the therapeutic efficacy of anticancer agents using GEM models.

Small molecule inhibitors have been used to target farnesyl transferase, epidermal growth factor receptor, and FLT3, using GEM models and have been predominantly shown to block tumor development or regress established malignancy (116, 128–130). RIP-Tag (pancreatic) and TRAMP (prostate) tumor progression models have been used to test the efficacy of angiogenesis/matrix metalloproteinase inhibitors (116, 131, 132), and vascular endothelial growth factor receptor inhibitors, respectively (133).

Additionally, very few studies have tested known clinically effective agents using GEM models (134–136). Such GEM studies using mice (whereby the equivalent mutation found in human malignancy is validated and therapeutic efficacy is observed) provides optimism that GEM models may indeed be of value in predicting clinical response. Despite such promise, the value of GEM mouse models in anticancer drug discovery is yet to be determined. Only time will tell if GEM models will be any better at predicting clinical activity than currently used xenograft models.

Compared to xenograft models, relatively few studies have documented the use of orthotopic (66, 79–81), transgenic (134–136), and autochthonous models (87) in cancer therapy and moreover in predicting clinical response. This is largely due to the fact that there are relatively few laboratories using these test systems in drug development programs. Additionally, unlike xenograft models (56), there are no studies collectively analyzing large bodies of data from these models, and therefore no definite conclusions can be made and the relative predictive value of orthotopic/autochthonous/transgenic models remains largely speculative. In order to assess the predictive value of these models, preclinical studies testing currently used chemotherapeutic agents are required.

With time it is anticipated that the clinical use of small molecule therapeutics will outweigh the use of classic cytotoxics. As the identification of specific pathways driving the development of human cancer increases, it is imperative that transgenic models are developed that truly reflect clinical disease. New drug molecules will have been identified through a rational preclinical cascade culminating in the demonstration of *in vivo* “proof of principle” of efficacy, in appropriate preclinical mouse models. It is essential for the validation of transgenic models that such small molecule therapeutics are evaluated in patients that have been appropriately selected on the basis of the expression of the molecular target.

## SUMMARY

As we have discovered more about the underlying mechanisms responsible for the initiation and progression of human cancers, we have experienced a move away from the development of classic cytotoxic agents to the rational design of small molecule anticancer therapeutics. This has prompted a transition from empirical compound-orientated preclinical screening to target-orientated drug screening. The use of uncharacterized tumor models (s.c. xenografts/syngeneic models) has been continuously replaced by more clinically relevant and molecularly characterized models along with the integration of pharmacodynamic and pharmacokinetic approaches.

The value of any preclinical tumor model will ultimately depend on its ability to accurately predict clinical response. In this modern era of target-driven anticancer drug discovery, we believe that the full potential of any tumor model can only be met if it is used “appropriately,” that is, if it is fully characterized to ensure that the molecular target of interest is expressed and that the model is used to confirm drug-target interaction. In addition to determining quantitative antitumor activity, it is believed that preclinical tumor models should be used to gain a broad range of information (i.e., pharmacokinetics/metabolism/pharmacodynamics). It is emphasized that this preclinical information needs to be used appropriately in clinical trials. In particular, if a novel target-directed agent is to be used to treat a patient, the presence of its respective target must initially be confirmed.

If preclinical models are used routinely to this extent and a closer relationship exists between the clinician and the laboratory scientist, it is anticipated that the clinical use of small molecule therapeutics will improve on the present clinical reality of classic cytotoxic chemotherapy identified using traditional uncharacterized models.

## REFERENCES

- Gellhorn A, Hirschberg E. Investigation of diverse systems for cancer chemotherapy screening. *Cancer Res* 1955;15:1–125.
- Goldin A, Venditti JM. Evaluation of chemical agents against carcinoma CA-755 in mice. *Cancer Res* 1961;21:617–91.
- Stock CC, Clarke DA, Philips FS, Barclay RK. Cancer chemotherapy screening data. V. Sarcoma 180 screening data. *Cancer Res* 1960;1–92.
- Oettel H, Wilhelm G. Tests of compounds against Ehrlich tumour, sarcoma 180 and Walker carcino-sarcoma 256. *Cancer Res* 1955;2:129–44.
- Goldin A, Venditti JM, Kline I, Mantel N. Evaluation of anti-leukemic agents employing advanced leukemia L1210 in mice. *Cancer Res* 1959;19:429–66.
- Plowman J. Human tumour xenograft models in NCI drug development. In: Teicher B, editor. *Anticancer drug development guide: preclinical screening, clinical trials, and approval*: Humana Press Inc.; 1997. p. 101–25.
- Geran RI, Greenberg NH, MacDonald MM, Schumacher AM, Abbott BJ. *Cancer Chemother Rep* 1972;3:1–103.
- Ovejera A, Johnson RK, Goldin A. *Cancer Chemother Rep* 1975;5:111–25.
- Venditti JM, Wesley RA, Plowman J. Current NCI preclinical antitumor screening *in vivo*: results of tumor panel screening, 1976–1982, and future directions. *Adv Pharmacol Chemother* 1984;20:1–20.
- DeVita VT, Schein PS. The use of drugs in combination for the treatment of cancer: rationale and results. *N Engl J Med* 1973;288:998–1006.
- Zubrod CG. Chemical Control of Cancer. *Proc Natl Acad Sci U S A* 1972;69:1042–7.
- Flanagan SP. “Nude”, a new hairless gene with pleiotropic effects in the mouse. *Genet Res* 1966;8:295–309.
- Rygaard J, Povlsen CO. Heterotransplantation of a human malignant tumour to “Nude” mice. *Acta Pathol Microbiol Scand* 1969;77:758–60.
- Bogden AE. A rapid screening method for testing chemotherapeutic agents against human tumour xenografts. In: Houchens D, Ovejera A, editors. *Proceedings of the Symposium of the Use of Athymic (Nude) Mice in Cancer Research*. New York, Stuttgart: Gustav Fischer; 1978. p. 231–50.
- Bogden AE. The subrenal capsule assay: biological properties and testing capability. In: Fiebig HH, Burger AM, editors. *Relevance of tumour models for anticancer drug development*. Contrib Oncol. Vol. 54. Basel: Karger; 1999. p. 89–99.
- Venditti JM. Drug evaluation branch program: report to screening contractors. *Cancer Chemother Rep* 1975;5:1–4.
- Staquet MJ, Byar DP, Green SB, Rozencweig M. Clinical predictivity of transplantable tumor systems in the selection of new drugs for solid tumors: rationale for a three-stage strategy. *Cancer Treat Rep* 1983;67:753–65.
- Venditti JM. Preclinical drug development: rationale and methods. *Semin Oncol* 1981;8:49–61.
- Salmon SE, Hamburger AW, Soehnlen B, et al. Quantitation of differential sensitivity of human-tumor stem cells to anticancer drugs. *N Engl J Med* 1978;298:1321–7.
- Hamburger AW, Salmon SE, Kim MB, et al. Direct cloning of human ovarian carcinoma cells in agar. *Cancer Res* 1978;38:3438–44.
- Von Hoff DD, Harris GJ, Johnson G, Glaubiger D. Initial experience with the human tumor stem cell assay system: potential and problems. *Prog Clin Biol Res* 1980;48:113–24.
- Shoemaker RH, Wolpert-DeFilippes MK, Kern DH, et al. Application of a human tumor colony-forming assay to new drug screening. *Cancer Res* 1985;45:2145–53.
- Bertelsen CA, Sondak VK, Mann BD, Korn EL, Kern DH. Chemosensitivity testing of human solid tumors. A review of 1582 assays with 258 clinical correlations. *Cancer* 1984;53:1240–5.
- Moon TE, Salmon SE, White CS, et al. Quantitative association between the *in vitro* human tumor stem cell assay and clinical response to cancer chemotherapy. *Cancer Chemother Pharmacol* 1981; 6:211–8.
- Tveit KM, Fodstad O, Lotsberg J, Vaage S, Pihl A. Colony growth and chemosensitivity *in vitro* of human melanoma biopsies. Relationship to clinical parameters. *Int J Cancer* 1982;29:533–8.
- Von Hoff DD, Casper J, Bradley E, et al. Association between human tumor colony-forming assay results and response of an individual patient’s tumor to chemotherapy. *Am J Med* 1981;70:1027–41.
- Von Hoff DD, Clark GM, Stogdill BJ, et al. Prospective clinical trial of a human tumor cloning system. *Cancer Res* 1983;43:1926–31.
- Salmon SE, Alberts DS, Durie BG, et al. Clinical correlations of drug sensitivity in the human tumor stem cell assay. *Recent Results Cancer Res* 1980;74:300–5.



29. Fiebig HH, Maier A, Burger AM. Clonogenic assay with established human tumour xenografts: correlation of *in vitro* to *in vivo* activity as a basis for anticancer drug discovery. *Eur J Cancer* 2004;40:802–20.
30. Selby P, Buick RN, Tannock I. A critical appraisal of the “human tumor stem-cell assay.” *N Engl J Med* 1983;308:129–34.
31. Fiebig HH, Schmid JR, Bieser W, Henss H, Lohr GW. Colony assay with human tumor xenografts, murine tumors and human bone marrow. Potential for anticancer drug development. *Eur J Cancer Clin Oncol* 1987;23:937–48.
32. Roth T, Burger AM, Dengler W, Willmann H, Fiebig HH. Human tumour cell lines demonstrating characteristics of patient tumours as useful models for anticancer drug screening. In: Fiebig HH, Burger AM, editors. *Relevance of tumour models for anticancer drug development*. Contrib Oncol. Vol. 54. Basel: Karger; 1999. p. 145–56.
33. Alley MC, Scudiero DA, Monks A, et al. Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. *Cancer Res* 1988;48:589–601.
34. Double JA, Bibby MC. Therapeutic index: a vital component in selection of anticancer agents for clinical trial. *J Natl Cancer Inst* 1989;81:988–94.
35. Corbett TH, Valeriote FA, Baker LH. Is the P388 murine tumour no longer adequate as a drug discovery model? *Invest New Drugs* 1987;5:3–20.
36. Boyd MR, Paull KD. Some practical considerations and applications of the National Cancer Institute *in vitro* anticancer drug discovery screen. *Drug Dev Res* 1995;34:91–109.
37. Holbeck SL. Update on NCI *in vitro* drug screen utilities. *Eur J Cancer* 2004;40:785–93.
38. Skehan P, Storeng R, Scudiero D, et al. New colorimetric cytotoxicity assay for anticancer-drug screening. *J Natl Cancer Inst* 1990;82:1107–12.
39. Paull KD, Shoemaker RH, Hodes L, et al. Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm. *J Natl Cancer Inst* 1989;81:1088–92.
40. Alvarez M, Paull K, Monks A, et al. Generation of a drug resistance profile by quantitation of Mdr-1/P-glycoprotein in the cell lines of the National Cancer Institute anticancer drug screen. *J Clin Invest* 1995;95:2205–14.
41. Hollingshead MG, Alley MC, Camalier RF, et al. *In vivo* cultivation of tumor cells in hollow fibers. *Life Sci* 1995;57:131–41.
42. Phillips RM, Bibby MC, Double JA. A critical appraisal of the predictive value of *in vitro* chemosensitivity assays. *J Natl Cancer Inst* 1990;82:1457–68.
43. Gorelik E, Ovejera A, Shoemaker R, et al. Microencapsulated tumor assay: new short-term assay for *in vivo* evaluation of the effects of anticancer drugs on human tumor cell lines. *Cancer Res* 1987;47:5739–47.
44. Lanza RP, Butler DH, Borland KM, et al. Xenotransplantation of canine, bovine, and porcine islets in diabetic rats without immunosuppression. *Proc Natl Acad Sci U S A* 1991;88:11100–4.
45. Lacy PE, Hegre OD, Gerasimidi-Vazeou A, Gentile FT, Dionne KE. Maintenance of normoglycemia in diabetic mice by subcutaneous xenografts of encapsulated islets. *Science* 1991;254:1785–4.
46. Decker S, Hollingshead M, Bonomi CA, Carter JP, Sausville EA. The hollow fibre model in cancer drug screening: the NCI experience. *Eur J Cancer* 2004;40:821–6.
47. Hall LA, Krauthauser CM, Wexler RS, et al. The hollow fiber assay: continued characterization with novel approaches. *Anticancer Res* 2000;20:903–11.
48. Suggitt M, Swaine DJ, Pettit GR, Bibby MC. Characterisation of the hollow fibre assay for the determination of microtubule disruption *in vivo*. *Clin Cancer Res*. 2004;10:6677–85.
49. Suggitt M, Bradshaw TD, Stevens MF, Bibby MC. 2-(4-amino-3-methylphenyl)benzothiazole prodrug (“Phortress”) causes selective DNA damage in breast carcinoma cells cultured in the *in vivo* hollow fibre assay. AACR-NCI-EORTC International Conference, Molecular Targets and Cancer Therapeutics [abstract]. 2003 Nov 17–21; Boston, MA, USA.
50. Suggitt M, Bibby MC. Characterisation of the hollow fibre assay for the analysis of DNA damage using the comet assay [abstract]. *Br J Cancer* 2003;88:S31.
51. Bibby MC, Suggitt M, Cooper PA, Thurston DE. *In vivo* drug/target interaction of the novel pyrrolbenzodiazepine dimer SJG-136 revealed using the hollow fibre assay. AACR-NCI-EORTC International Conference, Molecular Targets and Cancer Therapeutics [abstract]. 2003 Nov 17–21; Boston, MA, USA.
52. Krauthauser CM, Hall LA, Wexler RS, et al. Regulation of gene expression and cell growth *in vivo* by tetracycline using the hollow fiber assay. *Anticancer Res* 2001;21:869–72.
53. Sadar MD, Akopian VA, Beraldi E. Characterization of a new *in vivo* hollow fiber model for the study of progression of prostate cancer to androgen dependence. *Mol Cancer Ther* 2002;1:629–37.
54. Jonsson E, Friberg LE, Karlsson MO, et al. *In vivo* activity of CHS 828 on hollow-fibre cultures of primary human tumour cells from patients. *Cancer Lett* 2001;162:193–200.
55. Hollingshead M, Plowman J, Alley M, Mayo J, Sausville E. The hollow fiber assay. In: Fiebig HH, Burger AM, editors. *Relevance of tumour models for anticancer drug development*. Contrib Oncol. Vol. 54. 1999.
56. Johnson JI, Decker S, Zaharevitz D, et al. Relationships between drug activity in NCI preclinical *in vitro* and *in vivo* models and early clinical trials. *Br J Cancer* 2001;84:1424–31.
57. Phillips RM, Pearce J, Loadman PM, et al. Angiogenesis in the hollow fiber tumor model influences drug delivery to tumor cells: implications for anticancer drug screening programs. *Cancer Res* 1998;58:5263–6.
58. Hollingshead MG, Bonomi CA, Borgel SD, et al. A potential role for imaging technology in anticancer efficacy evaluations. *Eur J Cancer* 2004;40:890–8.
59. Sausville EA, Feigal E. Evolving approaches to cancer drug discovery and development at the National Cancer Institute, USA. *Ann Oncol* 1999;10:1287–91.
60. Plowman J, Camalier R, Alley M, Sausville E, Schepartz S. US-NCI testing procedures. In: Fiebig HH, Burger AM, editors. *Relevance of tumour models for anticancer drug development*. Contrib Oncol. Vol. 54. Basel: Karger; 1999. p. 121–35.
61. Kelland LR. Of mice and men: values and liabilities of the athymic nude mouse model in anticancer drug development. *Eur J Cancer* 2004;40:827–36.
62. Scholz CC, Berger DP, Winterhalter BR, Henss H, Fiebig HH. Correlation of drug response in patients and in the clonogenic assay with solid human tumour xenografts. *Eur J Cancer* 1990;26:901–5.
63. Steel GG, Courtenay VD, Peckham MJ. The response to chemotherapy of a variety of human tumour xenografts. *Br J Cancer* 1983;47:1–13.
64. Nam NH, Parang K. Current targets for anticancer drug discovery. *Curr Drug Targets* 2003;4:159–79.
65. Bibby MC. Transplantable tumours in mice—the way forward. In: Burger AM, editor. *Relevance of tumour models for anticancer drug development*. Contrib Oncol. Vol. 54. Basel: Karger; 1999. p. 1–13.
66. Bibby MC. Orthotopic models of cancer for preclinical drug evaluation: advantages and disadvantages. *Eur J Cancer* 2004;40:852–7.
67. Kerbel RS. Human tumor xenografts as predictive preclinical models for anticancer drug activity in humans: better than commonly perceived—but they can be improved. *Cancer Biol Ther* 2003;2:S134–9.
68. Peterson JK, Houghton PJ. Integrating pharmacology and *in vivo* cancer models in preclinical and clinical drug development. *Eur J Cancer* 2004;40:837–44.
69. Fichtner I, Slisow W, Gill J, et al. Anticancer drug response and expression of molecular markers in early-passage xenotransplanted colon carcinomas. *Eur J Cancer* 2004;40:298–307.
70. Takimoto CH. Why drugs fail: of mice and men revisited. *Clin Cancer Res* 2001;7:229–30.
71. Paget S. Secondary growths of cancer of breast. *Lancet* 1889;1:571–3.

72. Fidler IJ. Rationale and methods for the use of nude mice to study the biology and therapy of human cancer metastasis. *Cancer Metastasis Rev* 1986;5:29–49.
73. Fidler IJ, Naito S, Pathak S. Orthotopic implantation is essential for the selection, growth and metastasis of human renal cell cancer in nude mice [corrected]. *Cancer Metastasis Rev* 1990;9:149–65.
74. Hoffman RM. Fertile seed and rich soil: The development of clinically relevant models of human cancer by surgical orthotopic implantation of intact tissues. In: Teicher B, editor. *Anticancer drug development guide: preclinical screening, clinical trials, and approval*. Totowa, NJ: Humana Press, Inc.; 1997. p. 127–44.
75. Hoffman RM. Visualisation of metastasis in orthotopic mouse models with green fluorescent protein. In: Fiebig HH, Burger AM, editors. *Relevance of tumour models for anticancer drug development*. *Contrib Oncol*. Vol. 54. Basel: Karger; 1999. p. 81–7.
76. Killion JJ, Radinsky R, Fidler IJ. Orthotopic models are necessary to predict therapy of transplantable tumors in mice. *Cancer Metastasis Rev* 1999;17:279–84.
77. Kruger AE, Duray PH, Douglas K, et al. Approaches to preclinical screening of antiangiogenic agents. *Semin Oncol* 2001;28:570–6.
78. Tan MH, Holyoke ED, Goldrosen MH. Murine colon adenocarcinoma: syngeneic orthotopic transplantation and subsequent hepatic metastases. *J Natl Cancer Inst* 1977;59:1537–44.
79. Kuo TH, Kubota T, Watanabe M, et al. Site-specific chemosensitivity of human small-cell lung carcinoma growing orthotopically compared to subcutaneously in SCID mice: the importance of orthotopic models to obtain relevant drug evaluation data. *Anticancer Res* 1993;13:627–30.
80. Fidler IJ, Ellis LM. The implications of angiogenesis for the biology and therapy of cancer metastasis. *Cell* 1994;79:185–8.
81. Cowen SE, Bibby MC, Double JA. Characterisation of the vasculature within a murine adenocarcinoma growing in different sites to evaluate the potential of vascular therapies. *Acta Oncol* 1995;34:357–60.
82. Wang X, Fu X, Brown PD, Crimmin MJ, Hoffman RM. Matrix metalloproteinase inhibitor BB-94 (batimastat) inhibits human colon tumor growth and spread in a patient-like orthotopic model in nude mice. *Cancer Res* 1994;54:4726–8.
83. Hoffman R. Green fluorescent protein imaging of tumour growth, metastasis, and angiogenesis in mouse models. *Lancet Oncol* 2002;3:546–56.
84. Huss WJ, Maddison LA, Greenberg NM. Autochthonous mouse models for prostate cancer: past, present and future. *Semin Cancer Biol* 2001;11:245–60.
85. Lin WC, Pretlow TP, Pretlow TG II, Culp LA. Bacterial lacZ gene as a highly sensitive marker to detect micrometastasis formation during tumor progression. *Cancer Res* 1990;50:2808–17.
86. El Hilali N, Rubio N, Martinez-Villacampa M, Blanco J. Combined noninvasive imaging and luminometric quantification of luciferase-labeled human prostate tumors and metastases. *Lab Invest* 2002;82:1563–71.
87. Berger MR. Autochthonous tumour models in rats: Is there a relevance for anticancer drug development. In: Fiebig HH, Burger AM, editors. *Relevance of Tumour Models for Anticancer Drug Development*. *Contrib Oncol*. Vol. 54. Basel: Karger; 1999. p. 15–27.
88. Macleod KF, Jacks T. Insights into cancer from transgenic mouse models. *J Pathol* 1999;187:43–60.
89. Stewart TA, Pattengale PK, Leder P. Spontaneous mammary adenocarcinomas in transgenic mice that carry and express MTV/myc fusion genes. *Cell* 1984;38:627–37.
90. Adams JM, Cory S. Transgenic models for haemopoietic malignancies. *Biochim Biophys Acta* 1991;1072:9–31.
91. Knudson AG. Antioncogenes and human cancer. *Proc Natl Acad Sci U S A* 1993;90:10914–21.
92. Jacks T, Remington L, Williams BO, et al. Tumor spectrum analysis in p53-mutant mice. *Curr Biol* 1994;4:1–7.
93. Lavigne A, Maltby V, Mock D, et al. High incidence of lung, bone, and lymphoid tumors in transgenic mice overexpressing mutant alleles of the p53 oncogene. *Mol Cell Biol* 1989;9:3982–91.
94. Jacks T, Fazeli A, Schmitt EM, et al. Effects of an Rb mutation in the mouse. *Nature* 1992;359:295–300.
95. Donehower LA, Harvey M, Slagle BL, et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. *Nature* 1992;356:215–21.
96. Purdie CA, Harrison DJ, Peter A, et al. Tumour incidence, spectrum and ploidy in mice with a large deletion in the p53 gene. *Oncogene* 1994;9:603–9.
97. Moser AR, Mattes EM, Dove WF, et al. ApcMin, a mutation in the murine Apc gene, predisposes to mammary carcinomas and focal alveolar hyperplasias. *Proc Natl Acad Sci U S A* 1993;90:8977–81.
98. Jacks T, Shih T, Schmitt E. Tumorigenic and developmental consequences of a targeted Nf1 mutation in the mouse. *Nature Genet* 1994;3:353–61.
99. Herzig M, Christofori G. Recent advances in cancer research: mouse models of tumorigenesis. *Biochim Biophys Acta* 2002;1602:97–113.
100. Clarke AR. Manipulating the germline: its impact on the study of carcinogenesis. *Carcinogenesis* 2000;21:435–41.
101. Hann B, Balmain A. Building “validated” mouse models of human cancer. *Curr Opin Cell Biol* 2001;13:778–84.
102. Shoemaker AR, Gould KA, Luongo C, Moser AR, Dove WF. Studies of neoplasia in the Min mouse. *Biochim Biophys Acta* 1997;1332:F25–48.
103. Aszterbaum M, Epstein J, Oro A, et al. Ultraviolet and ionizing radiation enhance the growth of BCCs and trichoblastomas in patched heterozygous knockout mice. *Nat Med* 1999;5:1285–91.
104. Wasan HS, Novelli M, Bee J, Bodmer WF. Dietary fat influences on polyp phenotype in multiple intestinal neoplasia mice. *Proc Natl Acad Sci U S A* 1997;94:3308–13.
105. Kavanaugh C, Green JE. The use of genetically altered mice for breast cancer prevention studies. *J Nutr* 2003;133:2404–9S.
106. Vogelstein B, Kinzler KW. The multistep nature of cancer. *Trends Genet* 1993;9:138–41.
107. Sinn E, Muller W, Pattengale P, et al. Coexpression of MMTV/v-Ha-ras and MMTV/c-myc genes in transgenic mice: synergistic action of oncogenes *in vivo*. *Cell* 1987;49:465–75.
108. Hanahan D. Heritable formation of pancreatic  $\beta$ -cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes. *Nature* 1985;315:115–22.
109. Perl AK, Wilgenbus P, Dahl U, Semb H, Christofori G. A causal role for E-cadherin in the transition from adenoma to carcinoma. *Nature* 1998;392:190–3.
110. Naik P, Karrim J, Hanahan D. The rise and fall of apoptosis during multistage tumorigenesis: down-modulation contributes to tumor progression from angiogenic progenitors. *Genes Dev* 1996;10:2105–16.
111. Parangi S, Dietrich W, Christofori G, Lander ES, Hanahan D. Tumor suppressor loci on mouse chromosomes 9 and 16 are lost at distinct stages of tumorigenesis in a transgenic model of islet cell carcinoma. *Cancer Res* 1995;55:6071–6.
112. Bergers G, Hanahan D, Coussens LM. Angiogenesis and apoptosis are cellular parameters of neoplastic progression in transgenic mouse models of tumorigenesis. *Int J Dev Biol* 1998;42:995–1002.
113. Cavallaro U, Christofori G. Molecular mechanisms of tumor angiogenesis and tumor progression. *J Neurooncol* 2000;50:63–70.
114. Balmain A, Ramsden M, Bowden GT, Smith J. Activation of the mouse cellular Harvey-ras gene in chemically induced benign skin papillomas. *Nature* 1984;307:658–60.
115. Tuveson DA, Jacks T. Technologically advanced cancer modeling in mice. *Curr Opin Genet Dev* 2002;12:105–10.
116. Van Dyke T, Jacks T. Cancer modeling in the modern era: progress and challenges. *Cell* 2002;108:135–44.
117. Lewandoski M. Conditional control of gene expression in the mouse. *Nat Rev Genet* 2001;2:743–55.
118. Resor L, Bowen TJ, Wynshaw-Boris A. Unraveling human cancer

- in the mouse: recent refinements to modeling and analysis. *Hum Mol Genet* 2001;10:669–75.
119. Liyanage M, Coleman A, du Manoir S, et al. Multicolour spectral karyotyping of mouse chromosomes. *Nat Genet* 1996;14:312–5.
120. Pinkel D, Seagraves R, Sudar D, et al. High resolution analysis of DNA copy number variation using comparative genomic hybridization to microarrays. *Nat Genet* 1998;20:207–11.
121. Le Y, Sauer B. Conditional gene knockout using Cre recombinase. *Mol Biotechnol* 2001;17:269–75.
122. Lakso M, Sauer B, Mosinger B Jr, et al. Targeted oncogene activation by site-specific recombination in transgenic mice. *Proc Natl Acad Sci U S A* 1992;89:6232–6.
123. Johnson L, Mercer K, Greenbaum D, et al. Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. *Nature* 2001;410:1111–6.
124. Fisher GH, Orsulic S, Holland E, et al. Development of a flexible and specific gene delivery system for production of murine tumor models. *Oncogene* 1999;18:5253–60.
125. Weiss B, Shannon K. Mouse cancer models as a platform for performing preclinical therapeutic trials. *Curr Opin Genet Dev* 2003;13:84–9.
126. Jacks T. Tumor suppressor gene mutations in mice. *Annu Rev Genet* 1996;30:603–36.
127. Harlow E. Retinoblastoma. For our eyes only. *Nature* 1992;359:270–1.
128. Kohl NE, Omer CA, Conner MW, et al. Inhibition of farnesyl-transferase induces regression of mammary and salivary carcinomas in ras transgenic mice. *Nat Med* 1995;1:792–7.
129. Lenferink AE, Simpson JF, Shawver LK, et al. Blockade of the epidermal growth factor receptor tyrosine kinase suppresses tumorigenesis in MMTV/Neu + MMTV/TGF- $\alpha$  bigenic mice. *Proc Natl Acad Sci U S A* 2000;97:9609–14.
130. Levis M, Allebach J, Tse KF, et al. A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells *in vitro* and *in vivo*. *Blood* 2002;99:3885–91.
131. Bergers G, Javaherian K, Lo KM, Folkman J, Hanahan D. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. *Science* 1999;284:808–12.
132. Bergers G, Brekken R, McMahon G, et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. *Nat Cell Biol* 2000;2:737–44.
133. Huss WJ, Barrios RJ, Greenberg NM. SU5416 selectively impairs angiogenesis to induce prostate cancer-specific apoptosis. *Mol Cancer Ther* 2003;2:611–6.
134. Rego EM, He LZ, Warrell RP Jr, Wang ZG, Pandolfi PP. Retinoic acid (RA) and As2O3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RAR $\alpha$  and PLZF-RAR $\alpha$  oncoproteins. *Proc Natl Acad Sci U S A* 2000;97:10173–8.
135. Lallemand-Breitenbach V, Guillemin MC, Janin A, et al. Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemia. *J Exp Med* 1999;189:1043–52.
136. Bearss DJ, Subler MA, Hundley JE, et al. Genetic determinants of response to chemotherapy in transgenic mouse mammary and salivary tumors. *Oncogene* 2000;19:1114–22.

# Clinical Cancer Research

## 50 Years of Preclinical Anticancer Drug Screening: Empirical to Target-Driven Approaches

Marie Suggitt and Michael C. Bibby

*Clin Cancer Res* 2005;11:971-981.

**Updated version** Access the most recent version of this article at:  
<http://clincancerres.aacrjournals.org/content/11/3/971>

**Cited articles** This article cites 103 articles, 27 of which you can access for free at:  
<http://clincancerres.aacrjournals.org/content/11/3/971.full#ref-list-1>

**Citing articles** This article has been cited by 15 HighWire-hosted articles. Access the articles at:  
<http://clincancerres.aacrjournals.org/content/11/3/971.full#related-urls>

**E-mail alerts** [Sign up to receive free email-alerts](#) related to this article or journal.

**Reprints and Subscriptions** To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at [pubs@aacr.org](mailto:pubs@aacr.org).

**Permissions** To request permission to re-use all or part of this article, use this link  
<http://clincancerres.aacrjournals.org/content/11/3/971>.  
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.